✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

IPCA Laboratories Ltd

Common Name
IPCA Laboratories
Country
India
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
16,778
Ticker
IPCALAB
Exchange
NATIONAL STOCK EXCHANGE OF INDIA
Description
Ipca Laboratories Ltd. is a prominent Indian pharmaceutical company that develops, manufactures, and markets a vast array of pharmaceutical products and active pharmaceutical ingredients (APIs). Estab...

IPCA Laboratories's Financial Statements Preview

Below are the financial statements of IPCA Laboratories, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of INR
2025
2024
2023
Revenue from operations
89,395.9a
77,050.4b
62,443.2b
Other income
928a
1,247.7b
1,256.2b
Total income
90,323.9a
78,298.1b
63,699.4b
Expenses
Cost of materials consumed
-22,768.2a
-22,163.2b
-17,086.5b
Purchases of stock-in-trade
-
-4,900.7b
-4,971.9b
Changes in inventories of finished goods, work-in-progress and stock-in-trade
-
-1,306.4b
-1,006.7b
Employee benefits expense
-
-17,084.3b
-12,876.4b
Finance costs
-
-1,382.7b
-455.4b
Depreciation and amortisation expense
-
-3,572.4b
-2,615.6b
Other expenses
-
-20,997b
-17,234b
Total expenses
-
-68,793.9b
-56,246.5b
Profit from ordinary activity before share of profit/(loss) of associates & joint venture, exceptional items & tax
-
9,504.2b
7,452.9b
Exceptional items: (Income)/expenses
-
1,077.5b
-
Profit before tax
-
8,426.7b
7,452.9b
Tax expense
Current tax
-
-3,132.4b
-2,301.4b
Short/(excess) provision of earlier years
-
-30.6b
2.2b
Deferred tax liability/(asset)
-
-32.8b
-230b
Profit for the period from continuing operations before share of profit/(loss) of associates & joint venture
-
5,292.1b
4,919.3b
Add share of profit/(less loss) of associates & joint venture (net of tax) accounted by using the equity method
-
-62.9b
-129.4b
Profit for the period from continuing operations before non-controlling interest
-
5,229.2b
4,789.9b
Less profit/(add loss) attributable to non-controlling interest
-
-244.3b
76.7b
Profit for the period attributable to owners of the company
-
5,473.5b
4,713.2b
Revenue from operations
-
77,050.4a
-
Other income
-
1,247.7a
-
Total income
-
78,298.1a
-
Cost of materials consumed
-
-22,163.2a
-
Purchase of stock-in-trade
-5,477.8a
-4,900.7a
-
Changes in inventories of finished goods, work-in-progress and stock-in-trade
-460.5a
-1,306.4a
-
Employee benefit expense
-19,839.9a
-17,084.3a
-
Finance cost
-849.3a
-1,382.7a
-
Depreciation & amortisation expense
-3,978.2a
-3,572.4a
-
Other expenses
-24,509.1a
-20,997a
-
Total expenses
-76,962a
-68,793.9a
-
Profit from ordinary activity before share of profit/(loss) of associates & joint venture, exceptional items & tax
13,361.9a
9,504.2a
-
Exceptional items: (income)/expenses
2,050.5a
1,077.5a
-
Profit after exceptional item & before tax
11,311.4a
8,426.7a
-
Current tax
-3,731.4a
-3,132.4a
-
Short/(excess) provision of earlier years
-10.9a
-30.6a
-
Deferred tax liability/(asset)
-284.4a
-32.8a
-
Profit for the period from continuing operations before share of profit/(loss) of associates & joint venture
7,875.3a
5,292.1a
-
Share of profit/(loss) of associates & joint venture (net of tax) accounted by using the equity method
-22.9a
-62.9a
-
Profit for the period from continuing operations before non - controlling interest
7,852.4a
5,229.2a
-
Less/(add): Share of non-controlling interest - profit/(loss)
475.6a
-244.3a
-
Profit for the period attributable to owners of the company
7,376.8a
5,473.5a
-
Limited Data Preview
You are viewing a limited preview of IPCA Laboratories’s income statement data. The reported financial values are complete. The full dataset, available for download, additionally includes structured metadata for each line item, such as line item role (line item, subtotal, total) and financial classification (e.g., assets, liabilities, equity, revenue, expenses).
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research

Verified Sources Behind IPCA Laboratories’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore IPCA Laboratories’s data sources below and access millions more through our Disclosure Search.

a. IPCA Laboratories's Annual Report 2025
b. IPCA Laboratories's Financial Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?